Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tofacitinib for Treatment of Moderate COVID-19 (I-TOMIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04415151
Recruitment Status : Not yet recruiting
First Posted : June 4, 2020
Last Update Posted : June 4, 2020
Sponsor:
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-65 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Tofacitinib 10 mg Drug: Placebo Phase 2

Detailed Description:

The purpose of this randomized, double blinded, placebo controlled Phase 2b study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-65 years old) male and female patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation (see Inclusion criteria). Sixty patients will be recruited to receive tofacitinib or placebo in addition to standard of care (SOC) in a 2:1 ratio.

Subjects will be screened during hospitalization. Patients with confirmed SARS-CoV-2 infection, and meeting all other Inclusion and Exclusion criteria, will be randomized to either treatment with tofacitinib or placebo in addition to SOC during hospitalization (dose adjusted, if required), with the exception of any immunomodulatory agents (as documented in the inclusion/exclusion criteria). Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by need for supplementary oxygen), and will continue to be administered at 5 mg PO BID for a total duration of therapy of 14 days; follow-up off tofacitinib will continue up to Day 90. We anticipate completion of subject recruitment in 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC)
Estimated Study Start Date : June 30, 2020
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Tofacitinib
Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
Drug: Tofacitinib 10 mg
Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.

Placebo Comparator: Placebo
Matching placebo will be administered.
Drug: Placebo
Matching placebo tablets will be administered.




Primary Outcome Measures :
  1. Disease Severity [ Time Frame: 14 days ]
    The primary objective of this study is to determine whether tofacitinib improves the clinical outcomes of patients with moderate SARS-CoV-2 infection as determined by the primary outcome measure: Proportion of subjects alive and not needing any form of mechanical ventilation, high flow oxygen, or ECMO by day 14.


Secondary Outcome Measures :
  1. Clinical improvement [ Time Frame: 14 days ]

    Clinical improvement as measured by NIAID 8-point ordinal scale (i.e., 1 = death and 8 = Not hospitalized, no limitations on activities) at day 14.

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  2. Clinical improvement [ Time Frame: Up to 14 days ]

    Clinical improvement as measured by NIAID 8-point ordinal scale (i.e., 1 = death and 8 = Not hospitalized, no limitations on activities) (days 3 through day 14):

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  3. Time to recovery [ Time Frame: Up to 14 days ]

    Time to recovery [ Time Frame: Day 1 through Day 14] (Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale:

    1. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    2. Not hospitalized, limitation on activities and/or requiring home oxygen
    3. Not hospitalized, no limitations on activities)

  4. Time to clinical improvement [ Time Frame: 30 days ]

    Time to clinical improvement (defined as a 2-point increase on the NIAID 8-point ordinal scale (i.e., 1 = death and 8 = Not hospitalized, no limitations on activities).

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  5. Clinical status [ Time Frame: 30 Days ]

    Clinical status on the NIAID 8-point ordinal scale at day 30

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  6. Clinical status [ Time Frame: 60 Days ]

    Clinical status on the NIAID 8-point ordinal scale at day 60

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  7. Clinical status [ Time Frame: 90 Days ]

    Clinical status on the NIAID 8-point ordinal scale at day 90

    The scale is as follows:

    1. Death
    2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
    3. Hospitalized, on non-invasive ventilation or high flow oxygen devices
    4. Hospitalized, requiring supplemental oxygen
    5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
    6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care
    7. Not hospitalized, limitation on activities and/or requiring home oxygen
    8. Not hospitalized, no limitations on activities.

  8. Mortality [ Time Frame: 30 Days ]
    Mortality rate at day 30

  9. Mortality [ Time Frame: 60 Days ]
    Mortality rate at day 60

  10. Mortality [ Time Frame: 90 Days ]
    Mortality rate at day 90

  11. Mechanical Ventilatory Support [ Time Frame: Up to 14 Days ]
    Proportion of patients requiring mechanical ventilatory support.

  12. Mechanical Ventilatory Support Duration [ Time Frame: Up to 14 Days ]
    Duration of invasive mechanical ventilation (days).

  13. Freedom from mechanical ventilation [ Time Frame: Up to 14 Days ]
    Invasive mechanical ventilation free days.

  14. Adverse events [ Time Frame: Up to 14 days ]
    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

  15. Additional intervention [ Time Frame: Up to 14 days ]
    Did the patient receive an intervention with additional immunomodulatory agent (i.e. IL-6 targeting therapy)? (y/n)

  16. Viral titer [ Time Frame: Up to 14 days ]
    Change in SARS-CoV-2 viral titers during intervention.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  2. Participants with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other commercially available or public health assay prior to Day 1.
  3. Participants with evidence of pneumonia assessed by radiographic imaging (chest x ray or chest CT scan) AND Requiring ≥ 3L O2 OR ≥ 2L O2 and hsCRP > 70 mg/L
  4. Participants who are hospitalized and receiving supportive care for COVID-19.
  5. Participant (or legally authorized representative/surrogate) capable of giving signed informed consent.

Exclusion Criteria:

Medical Conditions:

  1. Require mechanical ventilation or ECMO on Day 1 at the time of randomization.
  2. Have current, or history of, venous thromboembolism (deep vein thrombosis or pulmonary embolism).
  3. Have a personal or first-degree family history of blood clotting disorders.
  4. Participants who are immunocompromised, with known immunodeficiencies, or taking potent immunosuppressive agents (eg, azathioprine, cyclosporine).
  5. Participants with any current malignancy or lymphoproliferative disorders that requires active treatment
  6. Females of child bearing potential who are pregnant or breastfeeding
  7. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk associated with study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  8. Anticipated survival < 72 hours as assessed by the Investigator.

Infection History:

• Suspected or known active systemic bacterial, fungal, or viral infections (with the exception of COVID-19) including but not limited to:

  • Secondary bacterial pneumonia;
  • Active herpes zoster infection;
  • Known active tuberculosis or history of inadequately treated tuberculosis;
  • Known HBV, HCV, or HIV.

Prior/Concomitant Therapy:

Have received any of the following treatment regimens specified in the timeframes outlined below:

Within 4 weeks prior to the first dose of study intervention:

  • Prior treatment with any JAK inhibitors, potent immunosuppressants, or any biologic agents including IL-6 inhibitors (eg, tocilizumab) or IL-1 inhibitors (eg, anakinra);
  • Prior treatment with any potent cytochrome P450 inducer, such as rifampin, within the past 28 days or 5 half-lives, whichever is longer.

Within 48 hours prior to the first dose of study intervention:

  • Treatment with corticosteroids equivalent to prednisone or methylprednisolone >20 mg/day;
  • Treatment with herbal supplements.

Diagnostic Assessments:

  • Severe hepatic impairment, defined as Child-Pugh class C.
  • Severe anemia (hemoglobin <8 g/dL).
  • ANY of the following abnormalities in clinical laboratory tests at screening, confirmed by a single repeat, if deemed necessary:
  • WBC <1000/mm3
  • Absolute lymphocyte count <500 cells/mm3;
  • Absolute neutrophil count <1000 cells/mm3.
  • Alanine transaminase/aspartate transaminase (ALT/AST) > 5 times the upper limit of normal;
  • Estimated glomerular filtration rate (eGFR) < 40 mL/min/1.73 m2);

Other Exclusions:

  • Known allergy to tofacitinib.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04415151


Contacts
Layout table for location contacts
Contact: Hyung Chun, MD (203) 785-6012 hyung.chun@yale.edu
Contact: Kelly Borges, MS, BS (203) 737-2737 kelly.borges@yale.edu

Sponsors and Collaborators
Yale University
Investigators
Layout table for investigator information
Principal Investigator: Hyung Chun, MD Yale School of Medicine
Layout table for additonal information
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT04415151    
Other Study ID Numbers: 2000027848
First Posted: June 4, 2020    Key Record Dates
Last Update Posted: June 4, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action